Sam Chun Dang Pharm (000250) Fundamentals 2026 — P/E 347.9x, Revenue Analysis | SniperIQ
Sam Chun Dang Pharm (000250) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩3.58T, trading at ₩152800.00 on the KOE. This SniperIQ fundamentals page covers Sam Chun Dang Pharm's valuation (P/E 347.9x, P/B 12.0x), profitability (net margin 4.2%), revenue (₩231.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sam Chun Dang Pharm's market cap?
Sam Chun Dang Pharm (000250) has a market capitalization of approximately ₩3.58T, trading at ₩152800.00 on the KOE. Market cap moves with the live share price.
What is Sam Chun Dang Pharm's P/E ratio?
Sam Chun Dang Pharm's trailing twelve-month P/E ratio is 347.9x, with a price-to-book (P/B) of 12.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sam Chun Dang Pharm?
Sam Chun Dang Pharm runs a net profit margin of 4.2%, a gross margin of 46.5%, and an operating margin of 5.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sam Chun Dang Pharm generate?
Sam Chun Dang Pharm reported revenue of ₩231.8B for fiscal year 2025, with net income of ₩5.3B and earnings per share (EPS) of 226.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sam Chun Dang Pharm pay a dividend?
Sam Chun Dang Pharm offers a trailing dividend yield of about 0.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sam Chun Dang Pharm financially healthy?
Sam Chun Dang Pharm carries a debt-to-equity ratio of 0.16x and a current ratio of 2.18x, with a market beta of 0.89. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sam Chun Dang Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sam Chun Dang Pharm (000250) the key facts are: market cap ₩3.58T, P/E 347.9x, revenue ₩231.8B, 52-week range 152800-1233000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sam Chun Dang Pharm's full fundamentals live
Get Sam Chun Dang Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.